Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marie Robin

Showing results (211-220 of 298) with videos related to

Pageof 30
Sort By:
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 21, 2014
Unrelated cord blood transplantation for patients with primary or secondary myelofibrosisMarie Robin, Federica Giannotti, Eric Deconinck, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 3, 2017
Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome Patients with a 5q DeletionLaurent Garderet, Dimitris Ziagkos, Anja van Biezen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 3, 2017
Dose-Reduced Versus Standard Conditioning Followed by Allogeneic Stem-Cell Transplantation for Patients With Myelodysplastic Syndrome: A Prospective Randomized Phase III Study of the EBMT (RICMAC Trial)Nicolaus Kröger, Simona Iacobelli, Georg-Nikolaus Franke, et al.
Bone Marrow Transplantation|January 23, 2022
Allogeneic hematopoietic cell transplantation in patients with myeloid/lymphoid neoplasm with FGFR1-rearrangement: a study of the Chronic Malignancies Working Party of EBMTJuan-Carlos Hernández-Boluda, Arturo Pereira, Nienke Zinger, et al.
Bone Marrow Transplantation|August 29, 2025
Conditioning intensity in myelodysplastic patients aged ≥ 50 years undergoing allogeneic hematopoietic cell transplantation (allo-HCT): a study on behalf of the chronic malignancies working party of the EBMTNoureddine Henoun Loukili, Luuk Gras, Linda Koster, et al.
Haematologica|March 23, 2023
Allogeneic transplantation in acute myelogenous leukemia: a comprehensive single institution's experienceGerard Socie, Jacques-Emmanuel Galimard, Emmanuel Raffoux, et al.
The Lancet. Haematology|August 10, 2025
Oral decitabine and cedazuridine maintenance after haematopoietic stem-cell transplantation in very high-risk acute myeloid leukaemia or myelodysplastic syndrome (GFM-DACORAL-DLI): a multicentre, single-arm, phase 2 trialMarie Robin, Maud D'Aveni, Aspasia Stamatoullas, et al.
American Journal of Hematology|August 29, 2025
Impact of Donor Type on Outcomes After Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis: A Study on Behalf of the Chronic Malignancies Working Party of the EBMTJuan Carlos Hernández-Boluda, Vipul Sheth, Simona Iacobelli, et al.
Current Research in Translational Medicine|September 13, 2018
Scoring System Based on Post-Transplant Complications in Patients after Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome: A Study from the SFGM-TCAlexis Caulier, Elodie Drumez, Jordan Gauthier, et al.
Bone Marrow Transplantation|October 2, 2021
Outcomes and toxicity of allogeneic hematopoietic cell transplantation in chronic myeloid leukemia patients previously treated with second-generation tyrosine kinase inhibitors: a prospective non-interventional study from the Chronic Malignancy Working Party of the EBMTStavroula Masouridi-Levrat, Eduardo Olavarria, Simona Iacobelli, et al.
Pageof 30

Showing results (211-220 of 298) with videos related to

Sort By:
Pageof 30
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 21, 2014
Unrelated cord blood transplantation for patients with primary or secondary myelofibrosisMarie Robin, Federica Giannotti, Eric Deconinck, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 3, 2017
Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome Patients with a 5q DeletionLaurent Garderet, Dimitris Ziagkos, Anja van Biezen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 3, 2017
Dose-Reduced Versus Standard Conditioning Followed by Allogeneic Stem-Cell Transplantation for Patients With Myelodysplastic Syndrome: A Prospective Randomized Phase III Study of the EBMT (RICMAC Trial)Nicolaus Kröger, Simona Iacobelli, Georg-Nikolaus Franke, et al.
Bone Marrow Transplantation|January 23, 2022
Allogeneic hematopoietic cell transplantation in patients with myeloid/lymphoid neoplasm with FGFR1-rearrangement: a study of the Chronic Malignancies Working Party of EBMTJuan-Carlos Hernández-Boluda, Arturo Pereira, Nienke Zinger, et al.
Bone Marrow Transplantation|August 29, 2025
Conditioning intensity in myelodysplastic patients aged ≥ 50 years undergoing allogeneic hematopoietic cell transplantation (allo-HCT): a study on behalf of the chronic malignancies working party of the EBMTNoureddine Henoun Loukili, Luuk Gras, Linda Koster, et al.
Haematologica|March 23, 2023
Allogeneic transplantation in acute myelogenous leukemia: a comprehensive single institution's experienceGerard Socie, Jacques-Emmanuel Galimard, Emmanuel Raffoux, et al.
The Lancet. Haematology|August 10, 2025
Oral decitabine and cedazuridine maintenance after haematopoietic stem-cell transplantation in very high-risk acute myeloid leukaemia or myelodysplastic syndrome (GFM-DACORAL-DLI): a multicentre, single-arm, phase 2 trialMarie Robin, Maud D'Aveni, Aspasia Stamatoullas, et al.
American Journal of Hematology|August 29, 2025
Impact of Donor Type on Outcomes After Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis: A Study on Behalf of the Chronic Malignancies Working Party of the EBMTJuan Carlos Hernández-Boluda, Vipul Sheth, Simona Iacobelli, et al.
Current Research in Translational Medicine|September 13, 2018
Scoring System Based on Post-Transplant Complications in Patients after Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome: A Study from the SFGM-TCAlexis Caulier, Elodie Drumez, Jordan Gauthier, et al.
Bone Marrow Transplantation|October 2, 2021
Outcomes and toxicity of allogeneic hematopoietic cell transplantation in chronic myeloid leukemia patients previously treated with second-generation tyrosine kinase inhibitors: a prospective non-interventional study from the Chronic Malignancy Working Party of the EBMTStavroula Masouridi-Levrat, Eduardo Olavarria, Simona Iacobelli, et al.
Pageof 30